Expertise in
15
conditions

Dr. Timothy P. Rearden

Internal Medicine
Washington University Cancer Center Pharmacy-North County
1255 Graham Rd, 
Florissant, MO 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Before you request
Expertise in
15
conditions
Washington University Cancer Center Pharmacy-North County
1255 Graham Rd, 
Florissant, MO 

Overview

Timothy Rearden is a primary care provider, practicing in Internal Medicine in Florissant, Missouri.

Dr. Rearden is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Breast Cancer, Small Cell Lung Cancer (SCLC), and Familial Colorectal Cancer.

He is actively involved in clinical research, co-authoring 4 peer reviewed articles and participating in 16 clinical trials. Dr. Rearden is currently accepting new patients.

Specialties

Internal Medicine

Licenses

Internal Medicine in MO

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

Washington University Cancer Center Pharmacy-North County
1255 Graham Rd, Florissant, MO 63031

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

Phase I/II Study of Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
Phase I/II Study of Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
Enrollment Status: Recruiting
Publish Date: February 11, 2026
Intervention Type: Radiation, Drug
Study Phase: Phase 1/Phase 2
Prospective Validation Trial of Taxane Therapy (Docetaxel or Weekly Paclitaxel) and Risk of Chemotherapy-Induced Peripheral Neuropathy in African American Women
Prospective Validation Trial of Taxane Therapy (Docetaxel or Weekly Paclitaxel) and Risk of Chemotherapy-Induced Peripheral Neuropathy in African American Women
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2026
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Paclitaxel
Study Phase: Phase 2
A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-Small Cell Lung Cancer
A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 16, 2026
Intervention Type: Procedure
Phase Ib/II Study to Evaluate Safety and Tolerability of Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer
Phase Ib/II Study to Evaluate Safety and Tolerability of Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer
Enrollment Status: Terminated
Publish Date: July 09, 2026
Intervention Type: Drug, Procedure, Biological
Study Drugs: Paclitaxel, Carboplatin, Nivolumab, Cabiralizumab
Study Phase: Phase 1/Phase 2
A Pilot Study to Evaluate the Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer
A Pilot Study to Evaluate the Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 08, 2026
Intervention Type: Drug
Study Drugs: Zimberelimab, Domvanalimab, Etrumadenant
Study Phase: Phase 2
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Phase 1b Clinical Trial of Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)
A Phase 1b Clinical Trial of Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)
Enrollment Status: Completed
Publish Date: November 12, 2025
Intervention Type: Drug, Procedure
Study Drugs: Cabozantinib, Nivolumab, Abiraterone, Prednisone
Study Phase: Phase 1
A Phase II Study of Maintenance Vorolanib and Atezolizumab in Patients With Extensive-stage SCLC
A Phase II Study of Maintenance Vorolanib and Atezolizumab in Patients With Extensive-stage SCLC
Enrollment Status: Terminated
Publish Date: November 03, 2025
Intervention Type: Drug
Study Drugs: Vorolanib, Atezolizumab
Study Phase: Phase 2
A Single Arm, Multicenter, Phase 2 Trial to Evaluate the Efficacy of Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)
A Single Arm, Multicenter, Phase 2 Trial to Evaluate the Efficacy of Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)
Enrollment Status: Terminated
Publish Date: March 21, 2025
Intervention Type: Procedure, Drug
Study Drugs: Lenvatinib, Pembrolizumab
Study Phase: Phase 2
Evaluating the Safety and Efficacy of Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial)
Evaluating the Safety and Efficacy of Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial)
Enrollment Status: Terminated
Publish Date: December 05, 2024
Intervention Type: Drug
Study Drugs: Mycophenolate Mofetil, Allopurinol, Irinotecan
Study Phase: Phase 1
View 9 Less Clinical Trials

4 Total Publications

A pilot study of nintedanib in molecularly selected patients with advanced non-small cell lung cancer.
A pilot study of nintedanib in molecularly selected patients with advanced non-small cell lung cancer.
Journal: Journal of thoracic disease
Published: January 17, 2024
Similar Doctors
Expertise in
28
conditions
Dr. Michael P. Whyte
Internal Medicine
Expertise in
28
conditions
Dr. Michael P. Whyte
Internal Medicine

Office

4921 Parkview Pl Ste 5C, 
Saint Louis, MO 
 (10.6 miles away)
314-454-7775
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Michael Whyte is a primary care provider, practicing in Internal Medicine in Saint Louis, Missouri. Dr. Whyte is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Hypophosphatasia (HPP), Juvenile Paget's Disease, Rickets, Osteopetrosis, and Leg or Foot Amputation. Dr. Whyte is currently accepting new patients.

Expertise in
13
conditions
Dr. John C. Morris
Internal Medicine
Expertise in
13
conditions
Dr. John C. Morris
Internal Medicine

Office

4488 Forest Park Ave Ste 160, 
Saint Louis, MO 
 (10.3 miles away)
314-286-1967
Languages Spoken:
English
See accepted insurances
Accepting New Patients

John Morris is a primary care provider, practicing in Internal Medicine in Saint Louis, Missouri. Dr. Morris is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Alzheimer's Disease, Dementia, Developmental Dysphasia Familial, Primary Amyloidosis, and Vertebroplasty. Dr. Morris is currently accepting new patients.

Expertise in
10
conditions
Dr. Richard D. Moore
Internal Medicine
Expertise in
10
conditions
Dr. Richard D. Moore
Internal Medicine

Precision Skin Care Dermatology LLC

10287 Clayton Rd Ste 360, 
Saint Louis, MO 
 (10.0 miles away)
314-863-5556
Languages Spoken:
English
See accepted insurances

Richard Moore is a primary care provider, practicing in Internal Medicine in Saint Louis, Missouri. Dr. Moore is highly rated in 10 conditions, according to our data. His clinical expertise encompasses HIV/AIDS, Sepsis, Hepatitis C, Hepatitis, and Gastrostomy.

Frequently Asked Questions about Dr. Timothy P. Rearden

How do I make an appointment with Dr. Timothy P. Rearden?

You can book an appointment with Dr. Timothy P. Rearden by calling their office at 314-820-6800. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Timothy P. Rearden a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Timothy P. Rearden is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Timothy P. Rearden specialize in?

While Dr. Timothy P. Rearden is a Internal Medicine, they have specific expertise in Lung Cancer, Breast Cancer, and Small Cell Lung Cancer (SCLC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Timothy P. Rearden participate in research or clinical trials?

Yes. Dr. Timothy P. Rearden has published 4 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Timothy P. Rearden's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Timothy P. Rearden accept my insurance?

Dr. Timothy P. Rearden accepts most major insurance plans, including Humana. We recommend calling the office directly at 314-820-6800 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rearden's expertise for a condition
ConditionClose
    View All 12 Advanced Conditions
    View All 60 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile